Kwells travel sickness tablets (12)

£3.35£8.99

Kwells travel sickness tablets melt in the mouth and provide fast relief from motion sickness.

Clear
SKU: Kwells travel sickness tablets (12) Categories: ,
Medication

Product Description

Kwells travel sickness tablets melt in the mouth and provide fast relief from motion sickness.

The active ingredient is Hyoscine hydrobromide, this acts on the nerves that create nausea.

The active ingredient in Kwells enters the bloodstream fast due to the melt in the mouth tablets.

Dosage

Tablets to be sucked, chewed or swallowed.

Adults:

1 tablet every 6 hours if required. Do not take more than 3 tablets in 24 hours.

Elderly:

There is no special dosage regimen for the elderly and as such caution should be exercised

Children:

Children over 10: ½-1 tablet every 6 hours if required. Do not take more than 1½-3 tablets in 24 hours.

Tablets to be taken up to 30 minutes before the start of the journey to prevent travel sickness, or at the onset of nausea.

Side Effects

The listed adverse drug reactions are based on spontaneous reports, thus an organization according to CIOMS II categories of frequency is not pertinent.

General: hyperthermia at high temperatures due to decreased sweating.

Eye disorders: blurred vision, mydriasis.

Gastrointestinal disorders: dry mouth.

Immune system disorders: allergic reaction and anaphylactic reaction. Hypersensitivity reactions with respective laboratory and clinical manifestations, including asthma syndrome, mild to moderate reactions affecting skin, respiratory tract, gastrointestinal tract, and cardiovascular system, and symptoms such as rash, urticaria, oedema, pruritus, cardio-respiratory distress, have been reported.

Nervous system disorders: drowsiness, dizziness, sedation and somnolence are commonly reported. Central nervous system stimulation including restlessness, hallucinations and confusion, have been less frequently reported following the administration of hyoscine.

There have been rare reports of an increase in seizure frequency in epileptic patients (the same caution for this patient population is included in Section 4.4).

Further Information